VERTO MD is a privately held service-providing company specializing in clinical research and development in the field of medical sciences and biotechnology, as well as the development, management, and monitoring of clinical trials. The main VERTO MD therapeutic areas include immunology and oncology, having experience in indications including but not limited to niche or orphan indications like CD30+, CD19+, CD20+ expressing malignancies, FcRn, PD-1/PDL-1 targeting, NOTCH signaling, TNFs, HDAC inhibition, proteasome inhibitors. We are part of global research activities and complex international projects in geographic areas such as the USA, European Union (EU) with strong expertise in Central and Eastern Europe (CEE); Middle East, Turkey, and Africa (META); South Asia & Australia (APAC); Russia & CIS; Latin America (LATAM); China and Hong Kong.